The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.

Phase I study of ixabepilone in combination with capecitabine in Japanese patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Background: Trabectedin (Tr) is ...